Granuloma Faciale Treated Successfully with Colchicine

Ohata, Chika; Nakama, Takekuni

doi:10.2340/00015555-3209

Cited by 6 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, control is regained over the inflammatory or autoimmune process that occurred in these patients. A similar use has been shown and a favorable outcome has been achieved with colchicine in patients with foreign body granuloma as an inflammatory tissue reaction to exogenous material (therapeutic embolization of the facial arteries), 16 or Granuloma faciale 17 and in cases of oleoma 18 (a non-allergic, foreign body type granulomatous reaction in response to oily exogenous substances injected into the dermis or subcutis for esthetical purposes).…”

Section: Clinical Cases Description: Iatrogenic Allogenosis Patients mentioning

confidence: 79%

Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients

Montealegre-Gómez

Garavito

Gómez-López

et al. 2021

Reumatología Clínica

View full text Add to dashboard Cite

COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article.

show abstract

Section: Clinical Cases Description: Iatrogenic Allogenosis Patients mentioning

confidence: 79%

Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients

Montealegre-Gómez

Garavito

Gómez-López

et al. 2021

Reumatología Clínica

View full text Add to dashboard Cite

show abstract

“…Granuloma faciale (GF) is an inflammatory dermatosis characterized by brownish‐red patches, plaques, papules, and nodules that mostly affect the face (Ohata & Nakama, ). Differential diagnosis for GF includes sarcoidosis, lymphoma, tumid lupus, cutaneous fungal infection erythema elevatum diutinum, and leishmaniasis (Santos‐Alarcon, Sanchis‐Sanchez, Ferrando‐Roca, & Mateu‐Puchades, ).…”

Section: Introductionmentioning

confidence: 99%

“…First‐line treatment of GF includes topical tacrolimus and corticosteroids. Further options are intralesional or systemic corticosteroids, topical and systemic dapsone, hydroxychloroquine, colchicine, cryosurgery, laser therapy, surgical procedures, topical pimecrolimus, clofazimine, and rituximab (Babalola, Zhang, Kristjansson, Whitaker‐Worth, & McCusker, ; Bobyr et al, ; Dourmishev, Ouzounova‐Raykova, Broshtilova, & Miteva, ; Jardim, Uchiyama, Kakizaki, & Valente, ; Lindhaus & Elsner, ; Micallef & Boffa, ; Morgado‐Carrasco, Giavedoni, Mascaro Jr., & Iranzo, ; Ohata & Nakama, ; Santos‐Alarcon et al, ; Shimoda‐Komatsu, Kinoshita‐Ise, Shimoyamada, & Ohyama, ; Wollina, Karte, Geyer, Stuhlert, & Bocker, ; Yuan et al, ). Here, we present the case of a patient who was switched to systemic dapsone after insufficient response to multiple treatments which showed excellent outcome.…”

Section: Introductionmentioning

confidence: 99%